ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

Home ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

/ Publications

Share the Post

About the Author

Related Posts

Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT
Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Read More
Caley Castelein, MD
Baiteng Zhao, PhD
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program

Comments

Comments are closed.